Free

Event Information

Share this event

Date and Time

Location

Location

Christopher Ingold Building

20 Gordon Street

London

WC1H 0AJ

United Kingdom

View Map

Event description

Description

We are excited to announce that we will be co-hosting the founders of COMPASS Pathways with the UCL Society for the Application of Psychedelics.

COMPASS proposes to use psilocybin (the psychoactive ingredient in "magic mushrooms") to treat treatment-resistant depression. Their trial, backed by investors such as Peter Thiel, was recently granted 'Breakthrough' status by the FDA.

George is a serial entrepreneur with significant experience in pharmaceutical regulation. He was previously CEO of TomorrowLab@McKinsey and also served as a senior advisor to McKinsey & Company’s leadership team.

Dr Ekaterina Malievskaia leads Research and Development at COMPASS. She completed an Environmental Medicine Fellowship at Mount Sinai School of Medicine and received her MSc in Public Health from New York University Medical School.

Seating will be allocated on a first come first served basis for those with a ticket and entry is guaranteed for members.

LSE NeuroSoc membership: https://bit.ly/2RTEGfQ
UCL SAP membership: https://bit.ly/2PjYsTS

https://compasspathways.com/

Share with friends

Date and Time

Location

Christopher Ingold Building

20 Gordon Street

London

WC1H 0AJ

United Kingdom

View Map

Save This Event

Event Saved